Vanguard Capital Management’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
Other funds holding SPRO
Vanguard Capital Management's SPRO Position: Q3 2026 in Review
Vanguard Capital Management held its Spero Therapeutics (SPRO) position steady in Q3 2026 at 2,036,226 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3314.
Vanguard Capital Management first reported a position in SPRO in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.5M in Q2 2026. 44 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.
- Vanguard Capital Management held 2,036,226 shares of Spero Therapeutics worth $2.46M as of Q3 2026.
- Vanguard Capital Management left its Spero Therapeutics share count unchanged in Q3 2026.
- Spero Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3314 holding.
- Vanguard Capital Management first reported a position in Spero Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Spero Therapeutics position peaked at $4.5M in Q2 2026.
- 44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.